Drug Trial Radar · NCT02608476
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)
Last checked: Nov 19, 2026Latest source record: Nov 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
732
Actual
Start
Nov 16, 2015
Primary completion
Feb 21, 2018
Study completion Feb 21, 2018
Sponsor
- Lead sponsor
- Cassiopea SpAIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
CB-03-01 cream, 1%Drug
CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Vehicle creamDrug
Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)Time frame: Week 12
- Change From Baseline in Non-inflammatory Lesion (NIL) CountsTime frame: Baseline and Week 12
- Change From Baseline in Inflammatory Lesion (IL) CountsTime frame: Baseline and Week 12
Locations
52 sites in 6 countries. Site status is shown where the registry gives one.
Clear dermatology & Aesthetic Center
Scottsdale, Arizona
Johnson Dermatology
Fort Smith, Arkansas
Center for Dermatology and Laser Surgery
Sacramento, California
Belleair Research Center
Pinellas Park, Florida
Arlington Dermatology
Arlington Heights, Illinois
Kansas City Dermatology, PA
Overland Park, Kansas
Maryland Laser Skin and Vein Institute
Hunt Valley, Maryland
Sadick Research Group, LLC
New York, New York
Skin Specialty Dermatology
New York, New York
Clinical Partners, LLC
Johnston, Rhode Island
Texas Dermatology and Laser Specialists
San Antonio, Texas
Progressive Clinical Research, PA
San Antonio, Texas
Site 3521
Plovdiv, Bulgaria
Site 3523
Sofia, Bulgaria
Site 3525
Sofia, Bulgaria
3520
Sofia, Bulgaria
Site 3524
Sofia, Bulgaria
Site 3519
Sofia, Bulgaria
Site 3526
Sofia, Bulgaria
Site 3522
Varna, Bulgaria
Site 9923
Batumi, Georgia
Site 9924
Kutaisi, Georgia
Site 9921
Tbilisi, Georgia
Site 9920
Tbilisi, Georgia
Site 9922
Tbilisi, Georgia
Site 9925
Zugdidi, Georgia
4819
Bydgoszcz, Poland
Site 4814
Częstochowa, Poland
Site 4822
Częstochowa, Poland
4815
Katowice, Poland
Site 4811
Katowice, Poland
Site 4821
Krakow, Poland
Site 4815
Krakow, Poland
Site 4813
Krakow, Poland
Site 4820
Lodz, Poland
Site 4823
Osielsko, Poland
Site 4816
Rzeszów, Poland
Site 4812
Szczecin, Poland
Site 4818
Warsaw, Poland
Site 4036
Bucharest, Romania
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.